Here we go again. The latest settlement in the parade was made by the Alpharma subsidiary of King Pharmaceuticals, as reported by Reuters:
Alpharma Inc, a unit of King Pharmaceuticals (KG.N), has agreed to pay $42.5 million to resolve allegations that it gave kickbacks to doctors to prescribe the pain drug Kadian and misrepresented its safety and effectiveness, the Justice Department said on Tuesday.
